Overview

Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

Status:
Unknown status

Trial end date:
2020-07-31

Target enrollment:

Participant gender:

Summary

Research hypothesis: Switching from dual regimens based on dolutegravir plus a RTI to a single tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), lowers the exposure to Residual Viremia (and hence the risk of viral rebound), without increasing treatment toxicity.

Phase:

Phase 3

Details

Lead Sponsor:

Ospedale San Raffaele

Collaborator:

Gilead Sciences

Treatments:

Cobicistat
Dolutegravir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Emtricitabine
Reverse Transcriptase Inhibitors